American Institute for Advanced Investment Management LLP Boosts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

American Institute for Advanced Investment Management LLP raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.8% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 7,052 shares of the company’s stock after acquiring an additional 125 shares during the period. American Institute for Advanced Investment Management LLP’s holdings in Johnson & Johnson were worth $992,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Hunter Perkins Capital Management LLC purchased a new stake in Johnson & Johnson during the second quarter valued at about $14,286,000. International Assets Investment Management LLC boosted its position in Johnson & Johnson by 3.3% during the second quarter. International Assets Investment Management LLC now owns 70,849 shares of the company’s stock valued at $2,161,000 after buying an additional 2,295 shares during the period. Graybill Bartz & Assoc Ltd. boosted its position in Johnson & Johnson by 1.5% during the second quarter. Graybill Bartz & Assoc Ltd. now owns 21,212 shares of the company’s stock valued at $2,983,000 after buying an additional 304 shares during the period. Evermay Wealth Management LLC boosted its position in Johnson & Johnson by 5.0% during the second quarter. Evermay Wealth Management LLC now owns 12,048 shares of the company’s stock valued at $1,694,000 after buying an additional 570 shares during the period. Finally, Signature Wealth Management Group boosted its position in Johnson & Johnson by 599.6% during the second quarter. Signature Wealth Management Group now owns 20,938 shares of the company’s stock valued at $2,945,000 after buying an additional 17,945 shares during the period. Institutional investors and hedge funds own 68.44% of the company’s stock.

Several analysts have issued reports on the stock. Wells Fargo & Co upgraded shares of Johnson & Johnson to a “hold” rating in a research report on Wednesday, April 22nd. ValuEngine downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Wednesday, July 15th. Argus reaffirmed a “buy” rating and set a $155.00 price objective (down from $165.00) on shares of Johnson & Johnson in a research note on Friday, March 27th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $168.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, April 28th. Finally, Credit Suisse Group reaffirmed a “buy” rating and set a $161.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, April 28th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $163.38.

Shares of NYSE JNJ opened at $150.01 on Thursday. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00. The company has a 50 day simple moving average of $143.94 and a two-hundred day simple moving average of $144.00. The company has a market capitalization of $394.50 billion, a price-to-earnings ratio of 18.79, a P/E/G ratio of 3.32 and a beta of 0.69. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.05 and a current ratio of 1.31.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Thursday, July 16th. The company reported $1.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.50 by $0.17. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.70%. The business had revenue of $18.34 billion during the quarter, compared to the consensus estimate of $17.73 billion. During the same quarter last year, the firm earned $2.58 earnings per share. The business’s revenue for the quarter was down 10.8% on a year-over-year basis. On average, analysts forecast that Johnson & Johnson will post 7.85 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a dividend of $1.01 per share. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date is Monday, August 24th. Johnson & Johnson’s dividend payout ratio is 46.54%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: What is the price-sales ratio?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.